454248-55-6

Basic information

• Product Name: tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate
• Synonyms: tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate;3-boc-4,4-dimethyl-2,2-dioxo-[1,2,3]oxathiazolidine;tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carbo
• CAS NO: 454248-55-6
• Molecular Formula: C9H17NO5S
• Molecular Weight: 251.3
• Mol File: 454248-55-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 297.5±23.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• PKA: -13.46±0.40(Predicted)
• CAS DataBase Reference: tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate(454248-55-6)
• EPA Substance Registry System: tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate(454248-55-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 454248-55-6(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate is a chemical compound with the molecular formula C10H17NO5S. It is commonly used as a reagent in organic synthesis and as a building block in the production of pharmaceuticals and agrochemicals. tert-butyl 4,4-Dimethyl-2,2-dioxooxathiazolidine-3-carboxylate is a derivative of oxathiazolidine-3-carboxylic acid and is known for its potential antifungal and antibacterial properties. It is also used in the preparation of various esters and amides due to its stable nature and ability to react with a wide range of functional groups. Additionally, it is known for its low toxicity and is widely used in the manufacturing industry.

Upstream product

• 102520-97-8 2-((tert-butyloxycarbonyl)amino)-2-methylpropan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 454248-45-4 tert-butyl 4,4-dimethyl-1,2,3-oxathiazolidine-3-carboxylate 2-oxide 

Relevant articles and documents

Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation

As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors. However, the use of the First-generation Trk inhibitors was greatly restricted due to mutant drug resistance. Fortunately, the emergence of the Second-generation of Trk inhibitors has brought an effective solution to this mutant resistance, such as TPX-0005 (Repotrectinib). Here, we reported a series of pyrizolo[1,5-a]pyrimidine derivatives as the second-generation Trk inhibitors, and carried out the subsequent biological activity evaluation. Among them, the best compound 14h (IC50 = 1.40, 1.80 nM, against TrkA, TrkAG595R, respectively) and 14j (IC50 = 0.86, 6.92 nM, against TrkA, TrkAG595R, respectively) has a kinase activity comparable to TPX-0005, and 14j (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition than TPX-0005, which may be of great significance for reducing toxicity.

Synthesis method for tert-butyl 1,2,3-oxathiazolidine-3-carboxylic ester 2,2-dioxide compound

The invention relates to a synthesis method for a tert-butyl 1,2,3-oxathiazolidine-3-carboxylic ester 2,2-dioxide compound. The tert-butyl 1,2,3-oxathiazolidine-3-carboxylic ester 2,2-dioxide compoundhas a structural formula as shown in a formula I which is described in the specification. The synthesis method comprises the step of allowing a compound as shown in a formula II which is described inthe specification with sulfonyl chloride in the presence of an organic solvent to generate the compound as shown in the formula I. The structural formula of the compound as shown in the formula I andthe structural formula of the compound as shown in the formula II are described in the specification. The synthesis method disclosed by the invention is simple to operate; compared with a conventional published two-step method, the synthesis method provided by the invention only needs one step; and the synthesis method is more convenient, reduces byproducts, is high in yield, does not need to usea catalyst and a highly-toxic substance in the reaction, and is safe and low in cost.

CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS

The invention provides compounds of formula (I) for use as GLP-1 receptor agonists.